Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CKD-348 T2, CKD-348 T1, CKD-828, D097, D337
Drug: CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,
Drug: CKD-828, D097, D337, CKD-348 T1, CKD-348 T2

First Posted Date: 2020-03-11

Last Posted Date: 2020-08-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 15

Registration Number: NCT04304547

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CKD-348 F1, CKD-348 F2, CKD-828, D326, D337

First Posted Date: 2020-02-17

Last Posted Date: 2020-02-17

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 15

Registration Number: NCT04272502

Locations: 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
Drug: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T
Drug: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T

First Posted Date: 2020-02-07

Last Posted Date: 2021-04-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT04260438

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348

Phase 1

Completed

Conditions: Hypertension
Dyslipidemias

Interventions: Drug: CKD-348 F1
Drug: CKD-348 F2
Drug: CKD-828, D097, D337

First Posted Date: 2020-02-06

Last Posted Date: 2020-06-05

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT04258865

Locations: 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495

Phase 3

Completed

Conditions: Gastritis

Interventions: Drug: CKD-495 75mg
Drug: Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Drug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Drug: Placebo of the CKD-495 75mg

First Posted Date: 2020-02-05

Last Posted Date: 2021-07-02

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 242

Registration Number: NCT04255589

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

and more 14 locations

A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396

Phase 1

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: CKD-501 and D759
Drug: CKD-396

First Posted Date: 2020-01-29

Last Posted Date: 2020-02-05

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 26

Registration Number: NCT04246190

Locations: 🇰🇷
Yonsei University Severance Hospital, Soeul, Korea, Republic of

Study to Evaluate the Efficacy and Safety of Tacrolimus in Kidney Transplant Recipients (BLOSSOM)

Phase 4

Conditions: Kidney Transplant

Interventions: Drug: Tacrolimus cap.
Drug: TacroBell SR cap.

First Posted Date: 2020-01-13

Last Posted Date: 2020-01-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 184

Registration Number: NCT04224350

Locations: 🇰🇷
The Catholic University of Korea, Seoul, St.Mary's Hospital., Seoul, Korea, Republic of

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers

Phase 1

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: CKD-386 Formulation 1
Drug: CKD-386 Formulation 2
Drug: D012, D326 and D337

First Posted Date: 2020-01-10

Last Posted Date: 2020-01-10

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT04223895

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375

Phase 1

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: CKD-375
Drug: D390

First Posted Date: 2020-01-09

Last Posted Date: 2020-01-09

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 26

Registration Number: NCT04221360

Locations: 🇰🇷
Yonsei University Severance Hospital, Soeul, Korea, Republic of

A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: CKD-506

First Posted Date: 2019-12-19

Last Posted Date: 2019-12-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 122

Registration Number: NCT04204603

Locations: 🇵🇱
182RA18009 Stie# PL07, Łódź, Poland
🇨🇿
182RA18009 Stie# CZ01, Uherské Hradiště, Czechia
🇨🇿
182RA18009 Stie# CZ05, Praha, Czechia

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy